NBCC shares jump 7% as Q4 EBITDA rises 19.3% YoY to Rs 290 crore
NBCC (India) Ltd. shares rose 7% after the company reported a solid financial performance for the fourth quarter ended March 31, 2025. As of 1:55 PM, the shares were trading 7.17% higher at Rs 124.53.
The public sector enterprise posted a 29.4% year-on-year increase in net profit, reaching ₹176 crore, compared to ₹136 crore in the same quarter last year.
Revenue for the quarter stood at ₹4,642.5 crore, marking a 16.2% rise from ₹3,996.3 crore reported in Q4FY24. The company also saw an improvement in its operating performance. EBITDA came in at ₹290 crore, up 19.3% from ₹243.2 crore a year ago. The EBITDA margin expanded slightly to 6.25%, compared to 6.09% in the corresponding period of the previous fiscal.
In addition to the earnings update, NBCC's board recommended a final dividend of ₹0.14 per equity share for the financial year 2024–25. The proposed dividend is subject to shareholder approval at the upcoming Annual General Meeting and is expected to be paid within 30 days from the date of declaration.
NBCC shares opened at ₹117.80, hitting a high of ₹126.70 and a low of ₹113.94 during the session. The stock remains volatile but shows strong momentum, nearing its 52-week high of ₹139.83.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025
BEIJING--(BUSINESS WIRE)--Beijing Avistone Biotechnology Co., Ltd ('Avistone'), an innovative biotechnology company focused on precision oncology therapeutics, today announced that the clinical data for Vebreltinib plus Andamertinib (PLB1004), its innovative combination of potent mesenchymal-epithelial transition factor (MET) inhibitor and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2025. The details of the poster presentation are provided below: Poster title: Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression after failure on EGFR-TKIs treatment: phase Ib/II KYLIN-1 study Abstract Number For Publication: 8632 Session: Poster Session-Lung Cancer- Non-Small Cell Metastatic Location: Poster Board, 112 Session Date/Time: 5/31/2025 1:30pm-4:30pm CDT MET amplification or overexpression is the most common 'off-target' mechanism that drives resistance to EGFR-TKIs in NSCLC patients. The results from Phase Ib/II KYLIN-1 study (NCT06343064) showed that Vebreltinib plus Andamertinib demonstrated notable efficacy and manageable safety in EGFR-mutated NSCLC patients with MET amplification or overexpression after EGFR-TKIs failure. Among the 56 patients enrolled at a dose of Vebreltinib 150mg BID plus Andamertinib 80mg QD (RP2D), the confirmed overall response rate (ORR) was 50.0%, and the median progression-free survival (mPFS) was 9.9 months. In 19 patients with brain metastases, ORR was 42.1% and mPFS was 9.5 months. Grade 3 or higher treatment related adverse events (TRAEs) occurred in 19.6% of the patients. None discontinued treatment or died due to TRAEs. No new safety signal was observed. A multicenter Phase III study, KYLIN-3 study (NCT06970782), is currently ongoing to further evaluate Vebreltinib plus Andamertinib versus platinum-based doublet chemotherapy in patients with EGFR mutations, MET amplification and/or overexpression, locally advanced or metastatic NSCLC following EGFR-TKI failure. To obtain a copy of the poster, please email Avistone. About Vebreltinib Vebreltinib is an orally, potent and selective c-Met inhibitor. Chinese National Medical Products Administration (NMPA) has formally approved the use of Vebreltinib in locally advanced or metastatic NSCLC patients with MET exon 14 skipping mutations, as well as adult patients with isocitrate dehydrogenase mutant astrocytoma with the PTPRZ1-MET fusion gene or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion gene and have failed previous treatments. Currently, Chinese Center for Drug Evaluation (CDE) has formally accepted its New Drug Application (NDA) and granted it priority review, intended for patients with locally advanced or metastatic NSCLC with MET amplification. About Andamertinib (PLB1004) Andamertinib (PLB1004) is an oral, potent, irreversible, and selective EGFR-TKI with potent blood-brain barrier penetration and broad tyrosine kinase activity. Preclinical studies have shown that it can effectively and irreversibly target exon 20 insertion. Additionally, it can also potently target classical EGFR mutations, such as Del19, L858R and T790M with a high degree of selectivity. About Avistone Biotechnology Beijing Avistone Biotechnology Co., Ltd. ('Avistone') is an innovative biotechnology company dedicated to precision therapies with significant unmet medical needs for patients worldwide. Avistone maintains an extensive pipeline of targeted therapies in Non-Small Cell Lung Cancer (NSCLC) and other solid tumors.
Hypebeast
2 hours ago
- Hypebeast
Cecilie Bahnsen Reimagines PORTER's Nylon Bags With Laser-Cut Florals
For the second installment ofYoshida & Co., Ltd.'s 90th anniversary roll-out, the manufacturer's legendaryPORTERline has enlistedCecilie Bahnsenfor a special collaboration reimagining its nylon bags with romantic motifs. The Danish designer, who has collaborated withAsicsandThe North Facein recent seasons, now turns her gaze towards accessories, incorporating her ever-present adornments into PORTER's utilitarian designs. Leading the collection is the backpack, available in an all-black nylon twill and decorated with black-on-black embroidery throughout the body and laser-cut flowers — Bahnsen's signature. The 2 Way Tool Bag, offered in classic olive green Khaki, a baby Gratian Blue, and Black, is a more directional silhouette, combining the likenesses of an elegant handbag and a tool carrier into one model. Finally, the smallest piece is the Bonsac Mini, offered in the same colorways, with a scaled-down design. On the new collaboration, Bahnsen said, 'This is a romantic act. It's about sorting through memories while deciding what to keep and what to reconstruct,' in a statement. Highlighting the power of quiet charm over flashy displays, Bahnsen's monochrome approach gives PORTER's durable nylon fabrics the spotlight. Simultaneously, the romantic sensibilities of the collection represent a contemporary facet of PORTER's visual identity as it inches towards 100 years in business. The Cecilie Bahnsen x PORTER collection is set for release on June 5 at PORTER's flagship store, PORTER SHINJUKU, andYoshida & Co.'s web store.
Yahoo
3 hours ago
- Yahoo
India's IndiGo to add 10 new international destinations to its network
(Reuters) -Indian airline IndiGo will add 10 international destinations and broaden its business class offerings overseas this year, CEO Pieter Elbers said on Friday, ramping up competition with rival Air India. The move marks a fresh push by IndiGo to tap into premium international travel, a space long dominated by Tata-owned Air India. IndiGo, which holds nearly 60% of India's domestic market, flew 1.8 million international passengers in the October–December quarter, just behind Air India and its budget unit's combined 2 million, DGCA data showed. The company will add business class seats on routes to Singapore, Phuket and Dubai, CEO Pieter Elbers said at an event in Delhi on Friday, without specifying the Indian departure points. The airline also plans to expand its long-haul network later this year with new destinations including London, Copenhagen, Athens, and Southeast Asian countries and cities like Hanoi and Cambodia. Earlier this year, IndiGo said it aims to increase international seat capacity and expand its fleet to over 600 aircraft by fiscal 2030. It has also signed a deal with Bengaluru International Airport to develop maintenance, repair and overhaul (MRO) infrastructure to support this growth. Connectez-vous pour accéder à votre portefeuille
